KLF14/miR-1283/TFAP2C axis inhibits HER2-positive breast cancer progression via declining tumor cell proliferation

被引:5
|
作者
Chen, Xue-Zhong [1 ]
He, Wen-Xing [1 ]
Luo, Rong-Guang [1 ]
Xia, Guo-Jin [1 ]
Zhong, Jin-Xiu [2 ]
Chen, Qing-Jie [1 ]
Huang, Yu-Ying [1 ]
Guan, Yan-Xing [1 ,3 ]
机构
[1] Nanchang Univ, Affiliated Hosp 1, Dept Nucl Med Radiol, Nanchang, Peoples R China
[2] Nanchang Univ, Affiliated Canc Hosp, Dept Breast Canc Ctr Nucl Med, Nanchang, Peoples R China
[3] Nanchang Univ, Affiliated Hosp 1, Dept Nucl Med Radiol, 17 Yong Wai St, Nanchang 330006, Peoples R China
基金
中国国家自然科学基金;
关键词
breast cancer; HER2; KLF14; miR-1283; proliferation; TFAP2C; AP-2-GAMMA; EXPRESSION; MICRORNAS;
D O I
10.1002/mc.23505
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
MiR-1283 has been identified as a tumor suppressor in some malignancies. Whereas, the role of miR-1283 in HER2-positive (HER2+) breast cancer, particularly its role in regulating cell proliferation, one of the most significant features of tumor progression, is unclear. The related microRNA screened by the breast cancer sample GSE131599 dataset were detected in HER2+ breast cancer tissues and cell lines. Then, the obtained miR-1283 was overexpressed in SKBR3 and BT-474 cells followed by relevant functional assays concerning cell proliferation and apoptosis. The xenograft mouse model was induced and the effect of miR-1283 on tumor growth and cell proliferation was examined. The target of miR-1283 and the transcription factor regulating miR-1283 were predicted and identified. Finally, the influence of transcription factor KLF14 on cell proliferation and apoptosis was investigated. An integrated analysis confirmed that miR-1283 expression was significantly decreased in HER2+ breast cancer tissues. Also, by q-RT-PCR detection, miR-1283 expression was markedly reduced in HER2+ breast cancer tissues and cell lines. The miR-1283 overexpression prevented the proliferation and enhanced apoptosis of HER2+ breast cancer cells, as well as inhibited tumor growth. Mechanistically, miR-1283 inhibited TFAP2C expression by targeting the 3 '-untranslated regions of TFAP2C messenger RNA, and the KLF14 enhanced miR-1283 level via binding to its promoter. The result subsequently confirmed the KLF14/miR-1283 signaling suppressed cell proliferation in HER2+ breast cancer. Our results suggested that the KLF14/miR-1283/TFAP2C axis inhibited HER2+ breast cancer progression, which might provide novel insight into mechanical exploration for this disease.
引用
收藏
页码:532 / 545
页数:14
相关论文
共 50 条
  • [21] Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions
    Andersson, Alma
    Larsson, Ludvig
    Stenbeck, Linnea
    Salmen, Fredrik
    Ehinger, Anna
    Wu, Sunny Z.
    Al-Eryani, Ghamdan
    Roden, Daniel
    Swarbrick, Alex
    Borg, Ake
    Frisen, Jonas
    Engblom, Camilla
    Lundeberg, Joakim
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [22] Syndecan-4 regulates the HER2-positive breast cancer cell proliferation cells via CK19/AKT signalling
    Pham, Son H.
    Vuorinen, Sofia I.
    Arif, K. M. Taufiqul
    Griffiths, Lyn R.
    Okolicsanyi, Rachel K.
    Haupt, Larisa M.
    BIOCHIMIE, 2023, 207 : 49 - 61
  • [23] Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft
    Lorena Landuzzi
    Arianna Palladini
    Claudio Ceccarelli
    Sofia Asioli
    Giordano Nicoletti
    Veronica Giusti
    Francesca Ruzzi
    Marianna L. Ianzano
    Laura Scalambra
    Roberta Laranga
    Tania Balboni
    Maddalena Arigoni
    Martina Olivero
    Raffaele A. Calogero
    Carla De Giovanni
    Massimiliano Dall’Ora
    Enrico Di Oto
    Donatella Santini
    Maria Pia Foschini
    Maria Cristina Cucchi
    Simone Zanotti
    Mario Taffurelli
    Patrizia Nanni
    Pier-Luigi Lollini
    Scientific Reports, 11
  • [24] Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft
    Landuzzi, Lorena
    Palladini, Arianna
    Ceccarelli, Claudio
    Asioli, Sofia
    Nicoletti, Giordano
    Giusti, Veronica
    Ruzzi, Francesca
    Ianzano, Marianna L.
    Scalambra, Laura
    Laranga, Roberta
    Balboni, Tania
    Arigoni, Maddalena
    Olivero, Martina
    Calogero, Raffaele A.
    De Giovanni, Carla
    Dall'Ora, Massimiliano
    Di Oto, Enrico
    Santini, Donatella
    Foschini, Maria Pia
    Cucchi, Maria Cristina
    Zanotti, Simone
    Taffurelli, Mario
    Nanni, Patrizia
    Lollini, Pier-Luigi
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [25] The HER2-targeted drug lapatinib inhibits the progression of breast cancer by regulating the miR-128-3p-BTG2 axis
    Yang, Huihui
    Wang, Wei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2021, 14 (02): : 864 - 873
  • [26] Simvastatin Downregulates HER2 via Upregulation of PEA3 to Induce Cell Death in HER2-Positive Breast Cancer Cells
    Zhao, Zhen
    Cao, Xiangming
    Pan, Yukai
    Sha, Sha
    Zhao, Tao
    Zhang, Tingrong
    ONCOLOGY RESEARCH, 2012, 20 (5-6) : 187 - 195
  • [27] miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
    Normann, Lisa Svartdal
    Haugen, Mads Haugland
    Aure, Miriam Ragle
    Kristensen, Vessela N.
    Molandsmo, Gunhild Mari
    Sahlberg, Kristine Kleivi
    BREAST CANCER-TARGETS AND THERAPY, 2022, 14 : 25 - 39
  • [28] A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers
    Hamalian, Sarkis
    Guth, Robert
    Runa, Farhana
    Sanchez, Francesca
    Vickers, Eric
    Agajanian, Megan
    Molnar, Justin
    Nguyen, Tuan
    Gamez, Joshua
    Humphries, Jonathan D.
    Nayak, Anupma
    Humphries, Martin J.
    Tchou, Julia
    Zervantonakis, Ioannis K.
    Kelber, Jonathan A.
    ONCOGENE, 2021, 40 (33) : 5224 - 5235
  • [29] A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers
    Sarkis Hamalian
    Robert Güth
    Farhana Runa
    Francesca Sanchez
    Eric Vickers
    Megan Agajanian
    Justin Molnar
    Tuan Nguyen
    Joshua Gamez
    Jonathan D. Humphries
    Anupma Nayak
    Martin J. Humphries
    Julia Tchou
    Ioannis K. Zervantonakis
    Jonathan A. Kelber
    Oncogene, 2021, 40 : 5224 - 5235
  • [30] Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER2-positive metastatic breast cancer
    Metro, G.
    Fabi, A.
    Giannarelli, D.
    Gemma, D.
    Ciccarese, M.
    Lanzetta, G.
    Papaldo, P.
    Lorusso, V.
    Magnolfi, E.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)